ISCO Moves Forward With Parkinson’s Disease Clinical Trials in Australia

CARLSBAD, CA–(Marketwired – November 03, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that after a recent meeting with Australian Therapeutics Goods Administration (TGA) the Company’s wholly owned subsidiary Cyto Therapeutics signed a Letter of Intent (LOI) with Royal Melbourne Hospital (Australia) to […]

Read More >>

ISCO Presents Comprehensive Findings for Parkinson’s Disease Program Preclinical Studies at the Society for Neuroscience Annual Meeting, Neuroscience 2015

CARLSBAD, CA–(Marketwired – October 14, 2015) – International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the Company will make an oral presentation on the comprehensive results of its preclinical development of human parthenogenetic neural stem cells (hPNSCs) for the treatment of Parkinson’s Disease at […]

Read More >>

ISCO Develops Technology to Replace Cartilage for the Treatment of Osteoarthritis

CARLSBAD, CA–(Marketwired – September 30, 2015) – International Stem Cell Corporation (OTCQB: ISCO)(www.internationalstemcell.com, ISCO or the Company), a California-based biotechnology company developing novel stem cell-based therapies, today announced that the Company’s scientific team has developed a robust innovative technology to generate functional articular cartilage from the patient’s own skin or adipose tissue to treat osteoarthritis. […]

Read More >>